Cognitive impairment in gynecologic cancers: a systematic review of current approaches to diagnosis and treatment
- First Online:
- 676 Downloads
To review the etiology and assessment of chemotherapy-related cognitive impairment (CRCI). To explore current treatment and prevention strategies for CRCI and propose future research goals in the field of gynecologic oncology.
Computerized searches in PubMed of cognitive impairment in cancer between 2000 and 2012 were conducted. The inclusion criteria were randomized control trials evaluating treatment of CRCI and search terms 'cognitive function, cognitive impairment, cognitive decline, chemobrain, chemofog, and cancer'.
To date, numerous modalities have been utilized for assessing CRCI in patients undergoing therapy. It has been proposed to move towards web-based assessment modalities as a possible standard. Few studies have aimed to elucidate possible treatment and prevention options for CRCI; even less in the field of gynecologic oncology. Only seven of these studies were subjected to randomized control trials. Only one of these studies looked at treatment in patients with gynecologic cancers.
The etiology of CRCI is multi-factorial. Following from this, there is no consensus on the best way to assess CRCI although objective measures are more reliable. One must extrapolate data from the non-gynecologic cancer literature, even venturing to non-cancer literature, to explore the treatment and prevention of CRCI. The methods found in these areas of research have not yet been applied to CRCI in gynecologic oncology.
KeywordsGynecologic cancer Chemotherapy-related cognitive impairment Treatment and prevention
- 3.cancer.org. Chemo brain. http://www.cancer.org/Treatment/TreatmentsandSideEffects/PhysicalSideEffects/ChemotherapyEffects/chemo-brain. Accessed October, 2012
- 9.Reiriz AB, Reolon GK, Preissler T, et al (2006) Cancer chemotherapy and cognitive function in rodent models: memory impairment induced by cyclophosphamide in mice. Clin Cancer Res;12(16):5000; author reply 5000–1Google Scholar
- 32.Meyers CA (2000) Neurocognitive dysfunction in cancer patients. Oncology (Williston Park). ;14(1):75–9; discussion 79, 81–2, 85Google Scholar
- 34.Suri D, Vaidya VA (2012) Glucocorticoid regulation of brain-derived neurotrophic factor: relevance to hippocampal structural and functional plasticity. NeuroscienceGoogle Scholar
- 42.Hensley ML, Correa DD, Thaler H et al (2006) Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: pathologic complete response and longitudinal assessment of impact on cognitive functioning. Gynecol Oncol 102(2):270–277CrossRefPubMedGoogle Scholar
- 59.Cohen K (1999) The way of qigong. 1st trade paperback ed. New York: Ballantine Books; 427Google Scholar